BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
RA Capital Management Wave Life Sciences Ltd. (WVE)
M&A
Other | 17.1% -0.4 13D/A [SEC] The Issuer entered into an Implementation Agreement providing for a Scheme of Arrangement under Singapore law, where all ordinary shares of the Issuer will be exchanged on a one-for-one basis for newly issued shares of common stock of Wave-Delaware, and the Issuer will become a subsidiary of Wave-Delaware. This Redomiciliation is conditioned on shareholder approval and will result in stockholder rights being governed by Delaware law. |
Baker Brothers Advisors BEONE MEDICINES LTD-ADR (ONC)
Board Seat
Other | 8.0% 13D/A [SEC] Felix J. Baker, Ph.D. was nominated to serve as a director and Lead Director of the Issuer until the 2027 annual general meeting. Michael Goller and Ranjeev Krishana, both employees of the Adviser, are not standing for re-election and their service is anticipated to expire on June 11, 2026. |
BIOS Partners Lantern Pharma Inc. (LTRN) | 7.4% -1.2 13D/A [SEC] |
Perceptive Advisors Zymeworks Inc. (ZYME) | 5.4% New 13G [SEC] |
RA Capital Management Vor Biopharma Inc. (VOR) | 19.9% 13D/A [SEC] |
Deerfield Management BiomX Inc. (PHGE) | 10.0% 13D/A [SEC] |
Redmile Group ABSCI CORP (ABSI) | 4.9% -0.5 13D/A [SEC] |
Perceptive Advisors KIORA PHARMACEUTICALS INC (KPRX) | 10.0% New 13G [SEC] |
RA Capital Management Adicet Bio, Inc. (ACET) | 12.3% +2.4 13G/A [SEC] |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
Perceptive Advisors KIORA PHARMACEUTICALS INC (KPRX) | 10.0% SC 13G [SEC] |
Perceptive Advisors Zymeworks Inc. (ZYME) | 5.4% SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.